Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.10 -0.9%	$1.69	$0.95 ▼ $2.96	$19.03M	0.05	371,195 shs	57,998 shs
IGMS IGM Biosciences	$1.08 -11.5%	$1.24	$0.92 ▼ $22.50	$72.93M	0.52	313,744 shs	2.43 million shs
IMUX Immunic	$0.70 -1.5%	$0.91	$0.56 ▼ $2.11	$68.07M	1.48	962,218 shs	747,317 shs
INCR InterCure	$1.49	$1.52	$1.17 ▼ $2.62	$67.90M	1.22	25,931 shs	25,620 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	-0.94%	+5.00%	+9.95%	+73.55%	-27.08%
IGMS IGM Biosciences	-11.48%	-7.69%	-12.90%	-12.90%	-83.86%
IMUX Immunic	-1.46%	-2.78%	-23.09%	-41.67%	-28.62%
INCR InterCure	0.00%	-1.97%	-3.56%	+5.67%	-31.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	0.876 of 5 stars	0.0	2.0	3.4	2.7	0.0	0.6
IGMS IGM Biosciences	4.2116 of 5 stars	3.0	4.0	4.6	1.0	3.3	0.6
IMUX Immunic	2.5099 of 5 stars	3.6	1.0	0.0	2.5	2.5	0.6
INCR InterCure	1.2808 of 5 stars	0.0	5.0	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	0.00	N/A	N/A	N/A
IGMS IGM Biosciences	1.90	Reduce	$5.50	409.26% Upside
IMUX Immunic	3.25	Buy	$11.60	1,557.14% Upside
INCR InterCure	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AYTU, IGMS, INCR, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/16/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/15/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81M	0.23	N/A	N/A	$4.64 per share	0.45
IGMS IGM Biosciences	$2.68M	24.09	N/A	N/A	$0.82 per share	1.32
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
INCR InterCure	$64.55M	1.05	N/A	N/A	$2.36 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	N/A
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-7,417.79%	-317.97%	-71.43%	8/13/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest AYTU, IGMS, INCR, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/14/2025	Q3 2025	AYTU Aytu BioPharma	-$0.17	$0.20	+$0.37	$0.21	$13.74 million	$18.45 million
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
IGMS IGM Biosciences	N/A	5.71	5.71
IMUX Immunic	N/A	0.74	0.74
INCR InterCure	0.34	1.73	1.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
IGMS IGM Biosciences	42.79%
IMUX Immunic	51.82%
INCR InterCure	8.34%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
IGMS IGM Biosciences	57.00%
IMUX Immunic	4.60%
INCR InterCure	0.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
IGMS IGM Biosciences	190	59.78 million	25.70 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable
INCR InterCure	350	45.57 million	45.46 million	Optionable

AYTU, IGMS, INCR, and IMUX Headlines

Recent News About These Companies

Short Interest in InterCure Ltd. (NASDAQ:INCR) Increases By 26.9%

June 18, 2025 | marketbeat.com

InterCure (NASDAQ:INCR) Stock Price Up 1.9% - What's Next?

June 5, 2025 | marketbeat.com

InterCure Ltd. (NASDAQ:INCR) Short Interest Up 21.5% in May

June 4, 2025 | marketbeat.com

InterCure Reports Strong Start to 2025 Amid Recovery Efforts

May 1, 2025 | tipranks.com

InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

May 1, 2025 | prnewswire.com

InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak

February 14, 2025 | markets.businessinsider.com

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

February 12, 2025 | prnewswire.com

InterCure Secures Major Funding to Boost Growth

December 22, 2024 | markets.businessinsider.com

Cannabis co InterCure raising NIS 66m for Nir Oz facility

December 22, 2024 | en.globes.co.ilE

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

December 20, 2024 | prnewswire.com

Rising High: Exclusive talk with house of brands Carma HoldCo

November 7, 2024 | markets.businessinsider.com

InterCure Ltd. (INCR)

October 16, 2024 | finance.yahoo.com

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

September 14, 2024 | benzinga.com

InterCure partners with Cookies to launch cannabis pharmacies in Germany

August 30, 2024 | investing.com

Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany

August 30, 2024 | msn.com

InterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

August 30, 2024 | finanznachrichten.de

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

August 29, 2024 | globenewswire.com

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

August 28, 2024 | finance.yahoo.com

Electreon Wireless Ltd (ELWS)

July 31, 2024 | investing.com

Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ

May 24, 2024 | markets.businessinsider.com

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

May 22, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
New Catalysts to Drive NVIDIA’s Stock Price Even Higher
By Thomas Hughes | June 16, 2025
View New Catalysts to Drive NVIDIA’s Stock Price Even Higher
Marvell's New AI Chip Deals Capture Wall Street’s Attention
By Jeffrey Neal Johnson | June 21, 2025
View Marvell's New AI Chip Deals Capture Wall Street’s Attention
Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
By Thomas Hughes | June 18, 2025
View Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow
Salesforce’s Stock Price Presents an Opportunity to Buy
By Thomas Hughes | May 29, 2025
View Salesforce’s Stock Price Presents an Opportunity to Buy

AYTU, IGMS, INCR, and IMUX Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.10 -0.02 (-0.94%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.02 (-1.19%)

As of 06/27/2025 07:55 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

IGM Biosciences NASDAQ:IGMS

$1.08 -0.14 (-11.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.18 +0.11 (+9.72%)

As of 06/27/2025 07:11 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Immunic NASDAQ:IMUX

$0.70 -0.01 (-1.46%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-3.00%)

As of 06/27/2025 07:59 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

InterCure NASDAQ:INCR

$1.49 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.58 +0.09 (+6.04%)

As of 06/27/2025 07:51 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time